What is Assembly Biosciences?
Assembly Biosciences, Inc. operates as a specialized clinical-stage biotechnology enterprise focused on the development of oral therapeutics. The company's core research pipeline targets the hepatitis B virus (HBV) infection, alongside a pioneering class of oral synthetic live biotherapeutics designed to restore health to a dysbiotic microbiome. By integrating advanced molecular biology with clinical rigor, Assembly Biosciences maintains a competitive market position, bridging the gap between complex viral pathology and patient-centric treatment solutions in the United States.
How much funding has Assembly Biosciences raised?
Assembly Biosciences has raised a total of $178.4M across 6 funding rounds:
Multiple Rounds
$20.8M
Private Equity
$12.6M
Private Equity
$30M
Stock/Share Issuance
$115M
Debt (2010): $2.7M, investors not publicly disclosed
Debt (2010): $700K, investors not publicly disclosed
Stock Issuance/Offering (2010): $17.4M, investors not publicly disclosed
Private Equity (2024): $12.6M featuring Armistice Capital and Gilead Sciences
Private Equity (2024): $30M backed by Gilead Sciences
Stock/Share Issuance (2026): $115M, investors not publicly disclosed
Key Investors in Assembly Biosciences
Gilead Sciences
Gilead Sciences is a global biopharmaceutical leader focused on discovering and commercializing innovative medicines for life-threatening diseases, including viral hepatitis and HIV/AIDS.
Armistice Capital
Armistice Capital is a global hedge fund employing a long/short, value-oriented, and event-driven investment strategy with a specialized focus on the healthcare and consumer sectors.
Undisclosed Investors
What's next for Assembly Biosciences?
With the recent influx of capital, Assembly Biosciences is poised to enter a critical phase of clinical expansion and operational scaling. The strategic focus will likely center on advancing its lead candidates through late-stage trials and optimizing its microbiome-based therapeutic platform. As the company navigates this growth trajectory, the integration of institutional support from key industry partners will be instrumental in navigating regulatory milestones and commercialization pathways. Investors and stakeholders are closely monitoring the firm's ability to translate its scientific pipeline into tangible clinical outcomes, which remains the primary driver of its long-term valuation and market influence.
See full Assembly Biosciences company page
